Sonoma Pharmaceuticals, Inc. announced its financial results for the third fiscal quarter and nine months ended December 31, 2024, on February 5, 2025. Revenues increased by 14% for the quarter compared to the prior year.
The company reported positive cash flow from operations for the quarter, with $5.2 million of cash on hand as of December 31, 2024. Year-to-date, the net loss declined by $1.1 million, indicating continued progress towards profitability.
Operating expenses remained flat during the quarter, demonstrating effective cost management in an inflationary period. These results highlight consistent revenue growth and improved financial health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.